The 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium was a huge success! We produced more than 20 interviews on topics ranging from the BOLERO-2 and CLEOPATRA trials (Jose Baselga) to medical economics (Eric Winer), breast cancer and the environment (Robert Hiatt), the treatment of young women with breast cancer (Ann Partridge), metastatic breast cancer [...]

  Dr. C. Kent Osborne, the co-director of the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), discusses breast cancer advances and treatment highlights over the past year. He highlights three areas which he thinks will be practice changing: the overall treatment of HER2-positive breast cancer, the findings from the BOLERO-2 trial and the use of [...]

  Dr. Jose Baselga discusses the exciting data for the HER2-negative breast cancer patient — the BOLERO-2 trial released at the CTRC-AACR 34th Annual San Antonio Breast Cancer Symposium. Dr. Baselga is the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and a Professor, Department of Medicine, Harvard [...]

  Dr. Jose Baselga discusses the exciting data for the HER2-positive breast cancer patient — the CLEOPATRA trial released at the CTRC-AACR 34th Annual San Antonio Breast Cancer Symposium. Dr. Baselga is the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and a Professor, Department of Medicine, Harvard [...]

  Dr. Eric Winer presented one of the plenary sessions at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. His talk was on endocrine therapy and looking into the future. His prognosis asks the question: Why haven’t we done better? And he addresses, what he believes, are the three key issues. Dr. Winer is [...]

  Dr. Robert A. Hiatt discusses the Institute of Medicine Report on Breast Cancer and the Environment: A Life-Course Approach, presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The report urges a life-course approach to studying breast cancer because new information suggests that women and girls might be more susceptible to some [...]

Dr. Julie R. Gralow discusses the SWOG SO226 where postmenopausal women with metastatic breast cancer given first-line treatment of fulvestrant (Faslodex) and anastrozole (Arimidix) have a better progression-free survival (PFS) than those given anastrozole alone. She also gives an update on bisphosphonates and osteonecrosis of the jaw at the 34th Annual CTRC-AACR San Antonio Breast [...]

  Dr. Clifford Hudis discusses what’s new with chemotherapy trials at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. He reviews eight posters from the conference that explored various chemotherapy-related questions. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill-Cornell Medical College [...]

  Dr. Clifford Hudis, through his discussion of the trial showing bevacizumab (Avastin) slows metastatic breast cancer, he highlights the important topic of the value of progression-free survival (PFS). This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan [...]

  Dr. Clifford Hudis discusses brain metastasis and a clinical trial ongoing at Memorial Sloan Kettering Cancer Center where researchers are testing chemotherapy penetration to the brain in a select group of trial-qualifying patients. This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Hudis is the Chief, Breast Cancer [...]